Stay up-to-date with the latest developments in securities law through access to both news and all statutes and regulations. Find relevant corporate filings through a searchable EDGAR database. And...
Aetna Inc. faces a shareholder class action claiming the health insurer undervalued its stock in connection with its proposed $77 billion merger with CVS Health Corp.
Aetna allegedly misled shareholders about the company’s financial projections and its financial adviser’s valuation analyses, according to a suit filed Jan. 16 in the U.S. District Court for the District of Connecticut. The shareholders said Aetna issued the misleading statements to encourage shareholders to vote in favor of the merger.
Aetna’s existing shareholders will get $145 cash and just under one share of CVS stock for each share of Aetna stock, valuing Aetna at about $207.94 per share, according to the complaint. The shareholders said Aetna’s stock is worth much more based on external valuations and growth predictions. Aetna’s own financial adviser gave the stock an implied per-share equity value of up to $233, according to the complaint.
The complaint seeks either to delay the merger vote until the misleading statements are corrected or damages based on the undervaluation. An Aetna representative said the company doesn’t comment on pending litigation.
Aetna and CVS will need regulatory approval for the deal, announced in early December.
The case is Miramond v. Aetna Inc. , D. Conn., No. 3:18-cv-00083, complaint filed 1/16/18 .
To contact the reporter on this story: Jennifer Bennett in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Seth Stern at email@example.com
Copyright © 2018 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)